Current Report Filing (8-k)
May 25 2022 - 5:11PM
Edgar (US Regulatory)
0001173313
false
0001173313
2022-05-20
2022-05-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 20, 2022
ABVC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Nevada |
|
333-91436 |
|
26-0014658 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
44370 Old Warm Springs Blvd.
Fremont, CA |
|
94538 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number including area
code: (510) 668-0881
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
|
ABVC |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
On
May 20, 2022, ABVC BioPharma, Inc. (the “Company”) held its 2022 annual meeting of shareholders (the “Annual
Meeting”). At the Annual Meeting, the Company’s shareholders voted on 5 proposals. At the beginning of the Annual Meeting,
16,239,330 shares of common stock, which represents 16,239,330 (53.58%) of the voting power of the shares entitled to vote at the Annual
Meeting, were represented by proxy, which constituted a quorum for the transaction of business.
We are filing this Current Report on Form 8-K
to disclose the voting results from the Annual Meeting.
| 1. | To re-elect 8 directors to the Company’s board of directors
(the “Board”), with such directors to serve until the 2023 annual meeting of shareholders. |
Name | |
For | | |
Against | | |
Withheld | |
Eugene Jiang | |
| 15,016,704 | | |
| - | | |
| 5,342 | |
Norimi Sakamoto | |
| 15,016,704 | | |
| - | | |
| 5,342 | |
Yen-Hsin Chou | |
| 15,016,604 | | |
| - | | |
| 5,442 | |
Dr. Tsung-Shann (T.S.) Jiang | |
| 15,016,704 | | |
| - | | |
| 5,342 | |
Dr. Shin-Yu Miao | |
| 15,016,704 | | |
| - | | |
| 5,342 | |
Yoshinobu Odaira | |
| 14,641,062 | | |
| - | | |
| 380,984 | |
Dr. Tsang Ming Jiang | |
| 15,016,204 | | |
| - | | |
| 5,842 | |
Dr. Chang-Jen Jiang | |
| 15,016,104 | | |
| - | | |
| 5,942 | |
| 2. | To elect 3 directors to the Company’s Board, with such directors to serve until the 2023 annual
meeting of shareholders. |
Name | |
For | | |
Against | | |
Withheld | |
Che Wei Hsu | |
| 15,016,704 | | |
| - | | |
| 5,342 | |
Shuling Jiang | |
| 14,605,046 | | |
| - | | |
| 417,000 | |
Kuang-Tseng Chen | |
| 15,016,104 | | |
| - | | |
| 5,942 | |
| 3. | To ratify the appointment of KCCW Accountancy Corp. (“KCCW”)
as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2022. |
For |
|
Against |
|
Abstain |
16,211,242 |
|
21,703 |
|
6,385 |
| 4. | An advisory (non-binding)
vote on executive compensation, also referred to as “say-on-pay” proposals, to endorse the compensation paid to our Named
Executive Officers, as disclosed in the proxy statement. |
For |
|
Against |
|
Abstain |
14,959,253 |
|
52,663 |
|
10,130 |
| 5. | An advisory (non-binding)
vote on the frequency of holding say-on-pay votes. In other words, how often we will include a say-on-pay proposal, similar to
Proposal No. 4, in our future proxy statements. |
Every Year |
|
Every 2 Years |
|
Every 3 Years |
|
Abstain |
466,164 |
|
2,136 |
|
14,543,446 |
|
10,300 |
Based on the votes, all proposals were approved
and the Company has decided to include a shareholder vote on the executive’s compensation in its proxy statements every three years.
SIGNATURE
Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ABVC BioPharma, Inc. |
|
|
|
May 25, 2022 |
By: |
/s/ Andy An |
|
|
Andy An |
|
|
Chief Financial Officer |
2
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABVC BioPharma (NASDAQ:ABVC)
Historical Stock Chart
From Apr 2023 to Apr 2024